This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

WEB REGISTRATION CLOSES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

David Bryson, PhD
Director, Gene Editing at Beam Therapeutics
Speaker

Profile

David is a Director of Gene Editing and Platform Technologies at Beam Therapeutics. David oversees protein engineering and directed-evolution efforts focused on lead optimization and platform development. He joined Beam in 2017 after completing postdoctoral research focused on directed evolution and genetic code expansion applications at Harvard and the Broad Institute. He obtained his PhD in Chemistry from Virginia Tech.

Agenda Sessions

  • Introduction to Base Editing Technology and Applications

    9:25am